Eduard Vieta

Last updated
Eduard Vieta
DrVieta.jpg
Born (1963-01-16) 16 January 1963 (age 61)
Barcelona, Spain
EducationAutonomous University of Barcelona
Medical career
Field Psychiatry
InstitutionsUniversity of Barcelona, Hospital Clinic of Barcelona
Sub-specialties Bipolar disorder
Website https://www.clinicbarcelona.org/profesionales/eduard-vieta

Eduard Vieta Pascual is a Catalan psychiatrist from Spain known for his work in the field of mood disorders. His unit is a world reference in clinical care, research and teaching of bipolar disorder and depression.

Contents

Education

Eduard Vieta was born in Barcelona, Spain. He studied medicine at the Autonomous University of Barcelona and graduated in 1987. He did his residency training at the Hospital Clinic of Barcelona and became a specialist in Psychiatry in 1991. He subsequently received his PhD with honors at the University of Barcelona in 1994.

Career

Research focus/interests

Dr. Vieta has focused his research activity on the study of the causes and the pharmacological and psychological treatment of bipolar disorder and depression, as well as in Precision Psychiatry. His contributions stand out for identifying neurocognitive dysfunctions and promoting the clinical development of new pharmacological treatments to address this condition. Additionally, his research has concentrated on psychotherapies such as psychoeducation and cognitive remediation to improve functioning and quality of life for patients with bipolar disorder. [1] Dr. Vieta has made contributions to numerous treatment guidelines for bipolar disorder [2] and is the founder of the concept of ‘Precision Psychiatry‘. [3]

Awards

Dr. Vieta has received the following awards:

Present and past appointments

Dr. Vieta is the current Head of the Psychiatry and Psychology Service of the Hospital Clínic of Barcelona and of the research group on bipolar and depressive disorders of the Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS), [16] [17] and is also a professor of Psychiatry at the Faculty of Medicine and Health Sciences and the Institute of Neurosciences of the University of Barcelona. Dr. Vieta was also the director of the Bipolar Disorder Research Program and scientific director of the Mental Health Network Research Center (CIBERSAM), [18] funded by the Spanish Ministry of Economy and Competitiveness, as well as former treasurer of the European College of Neuropsychopharmacology (ECNP). [19]

Dr. Vieta is the current editor-in-chief of the journal European Neuropsychopharmacology [20] and part of the European College of Neuropsychopharmacology (ECNP) Executive Committee (2022-2025) [21] . Additionally, he is on the editorial board of a number of international scientific journals, such as American Journal of Psychiatry, The Lancet Psychiatry, Psychotherapy Psychosomatics, the International Journal of Neuropsychopharmacology, European Neuropsychopharmacology, the Journal of Clinical Psychiatry, Bipolar Disorders, and the journal Journal of Affective Disorders. He was appointed to the Advisory Committee of the R&D&I Program in the Hungarian Presidency of the European Union. Considered among the psychiatrist with the best reputation in Spain (Health Monitor 2014 and Forbes), [22] he has been an advisor to the European presidency in neuroscience research, a visiting professor at Harvard University (United States) and an Honorary Doctor from the University of Valencia. [23]

Publications

To date, he has published more than 1,000 original articles in national and international journals, more than 500 book chapters and 50 books on bipolar disorder [24] . He currently accumulates more than 100,000 citations, and an h-index of 159, which has made him the most cited scientist in the world in bipolar disorder and one of the most cited in biomedical sciences (Highly Cited Scientist / Most influential Scientific Minds). [25]

Related Research Articles

<span class="mw-page-title-main">Kenneth L. Davis</span>

Kenneth L. Davis is the executive vice chairperson of the board of trustees at the Mount Sinai Health System in New York City, and an American author and medical researcher who developed the Alzheimer's Disease Assessment Scale, the most widely used tool to test the efficacy of treatments for Alzheimer's disease designed specifically to evaluate the severity of cognitive and noncognitive behavioral dysfunctions characteristic to persons with Alzheimer's disease. His research led to four of the first five FDA-approved drugs for Alzheimer's.

<span class="mw-page-title-main">Dennis S. Charney</span> American medical researcher

Dennis S. Charney is an American biological psychiatrist and researcher, with expertise in the neurobiology and treatment of mood and anxiety disorders. He is the author of Neurobiology of Mental Illness, The Physician's Guide to Depression and Bipolar Disorders and Molecular Biology for the Clinician, as well as the author of over 600 original papers and chapters. In 2022, he was listed #52 on Research.com's "Top Medicine Scientists in the United States," with an h-index of 194 with 146,109 citations across 651 publications. Charney is known for demonstrating that ketamine is effective for treating depression. Ketamine's use as a rapidly-acting anti-depressant is recognized as a breakthrough treatment in mental illness.

Guy Goodwin is a senior research fellow and until recently was the W.A. Handley Professor of Psychiatry at the University of Oxford (2014). A fellow of the Academy of Medical Sciences, Goodwin has served as principal investigator in many clinical trials for the treatment of bipolar disorder. He is also an Emeritus Senior Investigator at the National Institute for Health and Care Research (NIHR) and has been on the advisory boards of numerous research councils. He was President of the European College of Neuropsychopharmacology from 2013 to 2016.

Jules Angst is a Swiss academic who is Emeritus Professor of Psychiatry at Zurich University in Zurich, Switzerland, and Honorary Doctor of Heidelberg University in Heidelberg, Germany.

The European College of Neuropsychopharmacology (ECNP) is a pan-European, non-profit scientific association that serves as a platform to exchange and promote research in the field of neuropsychopharmacology. The ECNP “is committed to ensuring that advances in the understanding of brain function and human behaviour are translated into better treatments and enhanced public health”. The ECNP organises a number of activities to achieve this aim, such as a yearly congress, workshops, seminars, New Frontiers Meetings, publications, awards, supported talks and much more.

<span class="mw-page-title-main">Julio Vallejo Ruiloba</span> Spanish psychiatrist (1945–2019)

Julio Vallejo Ruiloba was a Spanish psychiatrist, medical doctor, Chairman of the Psychiatry Department at the Universitat de Barcelona, ex-President of the Spanish Psychiatry Society, and Academician of the Royal Academy of Medicine of Catalonia. He wrote 56 books about psychiatry and more than 350 scientific papers.

Celso Arango is a psychiatrist who has worked as a clinician, researcher, and educator in psychiatry and mental health, notably in the field of child and adolescent psychiatry, psychosis, and mental health promotion.

Mark J. Millan is a neuroscientist specialising in the study and improved treatment of disorders of brain. He was the Director of Pharmacological Innovation for the Central Nervous System (CNS) at the Institut de Recherché de Servier (IDRS) in Paris, France. He also served as the Secretary of the European College of Neuropsychopharmacology. Currently he is a Visiting Professor in the School of Psychology and Neuroscience at the University of Glasgow. Born in Edinburgh, he is the son of former Scottish Labour Party Leader and European Commissioner, Bruce Millan. He studied at Cambridge University and then spent ten years at the Max Planck Institute of Psychiatry, Munich, before moving to Paris.

<span class="mw-page-title-main">Gil Zalsman</span> Israeli psychiatrist and administrator

Gil Zalsman is an Israeli psychiatrist and child psychiatrist, the Director of the Geha Mental Health Center, Petach Tikva, Israel, where he also heads the Adolescent Day Unit.

Wim van den Brink is emeritus Professor of Psychiatry and Addiction at the Academic Medical Center, University of Amsterdam. He was Director of the Amsterdam Institute for Addiction Research (AIAR) and Scientific Director of the National Committee for Treatment of Heroin Addiction (CCBH) in Utrecht, the Netherlands.

Joseph Zohar is the director of Psychiatry and the Anxiety and Obsessive Compulsive Clinic at the Sheba Medical Center in Tel HaShomer and professor of psychiatry at Tel Aviv University, Israel. He is the founder of the World Council on Anxiety as well as the Israeli Consortium on PTSD. He currently leads the chief installation of the Israeli Defense Force for the treatment of PTSD. He is a member of the executive committee of the European College of Neuropsychopharmacology, of which he is a former president, and chairman of the Expert Platform on Mental Health.

Elisabeth Binder is a medical doctor and neuroscientist specializing in the study of mood and anxiety disorders. She is the director of the Department of Translational Research of the Max Planck Institute of Psychiatry in Munich, Germany. In addition to research, she serves as Vice-President of the European College of Neuropsychopharmacology (ECNP) and is a member of the Executive Committee.

Laurence Lanfumey-Mongredien is a neuroscientist specializing in preclinical research in neuroscience and molecular neuropsychopharmacology. Based at INSERM, she is the team leader of the “Pathophysiology of anxio-depressive and addictive disorders” research group. She is also a member of many scientific communities, most notably having served as a councilor on the executive committee of the European College of Neuropsychopharmacology.

Andreas Meyer-Lindenberg is a German psychiatrist and professor in the Medical Faculty Mannheim at Heidelberg University. He is also the director and CEO of the Central Institute of Mental Health in Mannheim, as well as medical director of their Department of Psychiatry and Psychotherapy. His research includes work on the genetics of complex psychiatric disorders. He has also used neuroimaging to study the neurobiological basis of mental disorders such as Williams Syndrome, and the effects of living in urban areas on mental health and the human brain.

<span class="mw-page-title-main">Haim Belmaker</span> Israeli professor of psychiatry

Prof. Robert Haim Belmaker, is an Israeli psychiatrist who has had major academic positions in Israeli psychiatry since 1974. He had a formative influence on biological directions in Israeli psychiatry. He was Hoffer-Vickar Professor of Psychiatry at Ben-Gurion University of the Negev, Beersheva Israel until his retirement and is now Emeritus.

René Sylvain Kahn is a neuropsychiatrist and the Esther and Joseph Klingenstein Professor and System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai in the United States, a position he has held since 2017. He previously served as Professor of Psychiatry and Director of the Brain Center Rudolf Magnus at the University Medical Center Utrecht in the Netherlands. Kahn is recognized for his research on the neurobiology of schizophrenia. He served as a former president of the Schizophrenia International Research Society and was elected to the Royal Netherlands Academy of Arts and Sciences in 2009. He received the Neuropsychopharmacology Award from the European College of Neuropsychopharmacology in 2014.

Mauricio Tohen is a Mexican American research psychiatrist, Distinguished Professor, and Chairman of the Department of Psychiatry & Behavioral Sciences at the University of New Mexico. Tohen's research has focused on the epidemiology, outcome, and treatment of bipolar and psychotic disorders, and is especially known for innovating the design of clinical trials and the criteria to determine outcome in such diseases. Tohen has edited several books on his specialties. His social awareness has been noted in the promotion of programs to improve mental health care in areas such as substance abuse, bipolar disorder and schizophrenia.

Marion Leboyer is a French psychiatrist, university professor and hospital practitioner at the Paris-Est Créteil University (UPEC).

Andreas Reif is a German psychiatrist. He is director of the Clinic for Psychiatry, Psychosomatics and Psychotherapy at the University Hospital Frankfurt.

Brenda Penninx is a Dutch researcher in psychiatry and professor of psychiatry epidemiology at the Free University of Amsterdam. She is one of the world's leading depression researchers.

References

  1. ↑ "Cambridge University Press". www.cambridge.org. Retrieved June 4, 2015.
  2. ↑ "The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2012 on the long-term treatment of bipolar disorder" (PDF). www.wfsbp.org. January 2013. Archived from the original (PDF) on March 4, 2016. Retrieved June 4, 2015.
  3. ↑ Vieta, Eduard; Salagre, Estela (July 2021). "Misunderstanding precision psychiatry". Psychological Medicine. 51 (9): 1418–1419. doi:10.1017/S0033291721001173. ISSN   0033-2917. PMID   34047266.
  4. ↑ "Mogens Schou Award". www.isbd.org. Archived from the original on July 7, 2015. Retrieved June 4, 2015.
  5. ↑ "El Dr. Vieta recibe el premio de investigación estratégica que otorga la Sociedad Española de Psiquiatría Biológica".
  6. ↑ "Eduard Vieta Pascual". CoMB (in Catalan). Retrieved 2024-05-03.
  7. ↑ "Eduard Vieta is Recognized for Outstanding Achievement in Mood Disorders Research". www.bbrfoundation.org. November 6, 2012. Archived from the original on June 8, 2015. Retrieved June 4, 2015.
  8. ↑ "CINP Awards Programme". www.cinp.org. Archived from the original on April 23, 2016. Retrieved June 4, 2015.
  9. ↑ "Doctor Honoris Causa by UV". www.idibaps.org. Archived from the original on April 12, 2016. Retrieved July 29, 2015.
  10. ↑ "Eduard Vieta, elegido mejor investigador del año por la Federación Mundial de Psiquiatría".
  11. ↑ "Eduard Vieta, premio Simón Bolívar por la Asociación Americana de Psiquiatría | CIBERISCIII". www.ciberisciii.es. Retrieved 2024-05-03.
  12. ↑ "Conócenos – SEPSM" (in Spanish). Retrieved 2024-05-03.
  13. ↑ "Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears". Acadèmia de Ciències Mèdiques i de la Salut de Catalunya i de Balears (in Spanish). Retrieved 2024-05-03.
  14. ↑ "Premios a la divulgación para el epidemiólogo Quique Bassat, la economista Judit Vall y el psiquiatra Eduard Vieta".
  15. ↑ "El IMIBIC reconoce al Dr. Eduard Vieta en su XIII Lección Conmemorativa Maimónides y premia los mejores trabajos de investigación 2022 - IMIBIC". www.imibic.org. Retrieved 2024-05-03.
  16. ↑ "Unidad de Trastornos Bipolares y Depresivos - IDIBAPS".
  17. ↑ "Eduard Vieta".
  18. ↑ "Eduard Vieta, nombrado nuevo director científico del CIBERSAM | CIBERSAM". www.cibersam.es. Retrieved 2024-05-03.
  19. ↑ "Past Executive Committees". www.ecnp.eu. Retrieved 2024-05-03.
  20. ↑ "European Neuropsychopharmacology - Editorial board".
  21. ↑ "The Executive Committee". www.ecnp.eu. Retrieved 2024-07-30.
  22. ↑ isanidad (2021-01-13). "Forbes destaca a los cuatro mejores médicos en Psiquiatría". iSanidad (in Spanish). Retrieved 2024-05-03.
  23. ↑ "Acto de Investidura como Doctor "Honoris Causa" de l'Excm. Sr. Dr. Eduard Vieta Pascual". www.uv.es. Retrieved 2024-05-03.
  24. ↑ "ORCID". orcid.org. Retrieved 2024-07-30.
  25. ↑ "Web of Science". www.webofscience.com. Retrieved 2024-05-03.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.